- Home
- CUK vs BIIB Comparison
CUK vs BIIB Comparison
Compare CUK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUK
- BIIB
- Stock Information
- Founded
- CUK 1972
- BIIB 1978
- Country
- CUK United States
- BIIB United States
- Employees
- CUK N/A
- BIIB N/A
- Industry
- CUK Marine Transportation
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CUK Consumer Discretionary
- BIIB Health Care
- Exchange
- CUK Nasdaq
- BIIB Nasdaq
- Market Cap
- CUK 26.6B
- BIIB 18.8B
- IPO Year
- CUK 2000
- BIIB 1991
- Fundamental
- Price
- CUK $25.00
- BIIB $125.00
- Analyst Decision
- CUK Buy
- BIIB Buy
- Analyst Count
- CUK 17
- BIIB 27
- Target Price
- CUK $27.00
- BIIB $188.17
- AVG Volume (30 Days)
- CUK 2.5M
- BIIB 1.3M
- Earning Date
- CUK 06-24-2025
- BIIB 07-31-2025
- Dividend Yield
- CUK N/A
- BIIB N/A
- EPS Growth
- CUK 160.22
- BIIB 26.39
- EPS
- CUK 1.84
- BIIB 10.12
- Revenue
- CUK $25,972,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- CUK $7.03
- BIIB N/A
- Revenue Next Year
- CUK $3.43
- BIIB N/A
- P/E Ratio
- CUK $14.43
- BIIB $12.41
- Revenue Growth
- CUK 10.82
- BIIB 1.59
- 52 Week Low
- CUK $12.65
- BIIB $110.04
- 52 Week High
- CUK $26.14
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- CUK 71.40
- BIIB 45.14
- Support Level
- CUK $20.40
- BIIB $123.21
- Resistance Level
- CUK $23.89
- BIIB $129.27
- Average True Range (ATR)
- CUK 0.61
- BIIB 3.00
- MACD
- CUK 0.18
- BIIB -0.77
- Stochastic Oscillator
- CUK 98.52
- BIIB 21.06
About CUK Carnival Plc ADS ADS
Carnival is the largest global cruise company, with more than 90 ships in service at the end of fiscal 2024. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.